Description

Anecortave Acetate (CAS: 7753-60-8) is a synthetic corticosteroid derivative with the molecular formula C₂₃H₃₀O₅. This compound, also known by its IUPAC name [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate, is a potent angiostatic steroid that inhibits neovascularization. It is widely utilized in ophthalmic research and therapeutic applications due to its unique mechanism of action, which involves suppressing the growth of abnormal blood vessels without exhibiting glucocorticoid or mineralocorticoid activity. Anecortave Acetate is supplied as a high-purity powder, ensuring optimal performance in experimental and clinical settings. Its stability and solubility profiles make it suitable for various formulations, including suspensions and injectables.

Properties

• CAS Number: 7753-60-8
• Complexity: 808
• IUPAC Name: [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] acetate
• InChI: InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1
• InChI Key: YUWPMEXLKGOSBF-GACAOOTBSA-N
• Exact Mass: 386.20932405
• Molecular Formula: C23H30O5
• Molecular Weight: 386.5
• SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC=C3[C@H]2CCC4=CC(=O)CC[C@@]43C)C)O
• Topological: 80.7
• Monoisotopic Mass: 386.20932405
• Synonyms: Anecortave acetate, Retaane, Retaane suspension, AL-3789, Anecortave acetate [USAN], Al 3789, NSC 15475, NSC 24345, NSC-15475, NSC-24345, Y0PC411K4T, 17,21-Dihydroxypregna-4,9(11)-diene-3,20-dione 21-Acetate, DTXSID5046805, EINECS 231-812-5, 21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione, ANECORTAVE [MART.], ANECORTAVE ACETATE [MI], ANECORTAVE ACETATE [JAN], DTXCID3026805, ANECORTAVE (MART.), HYDROCORTISONE ACETATE IMPURITY E [EP IMPURITY], 4,9(11)-pregnadien-17alpha,21-diol-3,20-dione-21-acetate, HYDROCORTISONE ACETATE IMPURITY E (EP IMPURITY), 2-((1R,3aS,3bS,9aS,11aS)-1-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,11H,11aH-cyclopenta(a)phenanthren-1-yl)-2-oxoethyl acetate, 2-[(1R,3aS,3bS,9aS,11aS)-1-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate, 7753-60-8, Anecortave [INN], ANECORTAVE ACETATE F0E2980.997MG/MG(AI), AL3789, [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate, 17-Hydroxy-3,20-dioxopregna-4,9(11)-dien-21-yl acetate, UNII-Y0PC411K4T, anecortave-acetate, NCGC00181018-01, SCHEMBL94110, 17-Hydroxy-3,20-dioxopregna-4,9(11)-dien-21-yl acetate #, Anecortave acetate (JAN/USAN), CHEMBL2106613, CHEBI:31215, ANECORTAVE ACETATE (200 MG)F0E2980.997MG/MG(AI), EX-A5253, NSC15475, NSC24345, Tox21_112668, 17-alpha,21-Dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate, AKOS015917580, DB05288, FA17919, 2-((8S,10S,13S,14S,17R)-17-Hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate, DA-50466, TS-08155, CAS-7753-60-8, HY-116868, CS-0066714, NS00037926, D01733, G76948, Q4761567, 21-acetoxy-17-hydroxy-4,9(11)-pregnadiene-3,20-dione, 17alpha-hydroxy-21-acetoxypregna-4,9(11)-diene-3,20-dione, Pregn-4,9(11)-dien-17,21-diol-3,20-dione, acetate(ester), 17alpha-hydroxy-21 -acetoxy-pregna-4,9(11)-diene-3,20-dione, Pregna-4,9(11)-diene-3,20-dione, 21-(acetyloxy)-17-hydroxy-, 21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione;17,21-Dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate

Application

Anecortave Acetate is primarily used in ophthalmology for the treatment of age-related macular degeneration (AMD) and other ocular neovascular disorders. Its angiostatic properties make it effective in inhibiting choroidal neovascularization, a key factor in AMD progression. Researchers also employ this compound in preclinical studies to explore its potential in treating other vascular proliferative diseases. Its lack of glucocorticoid activity reduces the risk of side effects commonly associated with traditional corticosteroids.

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.